Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1181-1190 of 1,281) with videos related to

Pageof 129
Sort By:
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
Therapeutic Advances in Medical Oncology|December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutationsNadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
British Journal of Cancer|February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsPetra Martin, Carolyn J Shiau, Maria Pasic, et al.
Breast Cancer Research and Treatment|March 5, 2018
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristicsMegan S Rice, Rulla M Tamimi, Kimberly A Bertrand, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohortY Li, M Wong, L Zhan, et al.
Therapeutic Advances in Medical Oncology|September 26, 2022
Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsyMiguel Garcia-Pardo, Kasia Czarnecka, Jennifer H Law, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2020
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft modelsSebastiao N Martins-Filho, Jessica Weiss, Nhu-An Pham, et al.
The Oncologist|April 7, 2019
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence AnalysisGrainne M O'Kane, Jie Su, Brandon C Tse, et al.
Clinical Lung Cancer|May 17, 2025
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase InhibitorsLouis Pinard, Avinash Rao Ullur, Louis Everest, et al.
Pageof 129

Showing results (1181-1190 of 1,281) with videos related to

Sort By:
Pageof 129
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
Therapeutic Advances in Medical Oncology|December 30, 2024
Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutationsNadia Ghazali, Jamie Feng, Katrina Hueniken, et al.
British Journal of Cancer|February 19, 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsPetra Martin, Carolyn J Shiau, Maria Pasic, et al.
Breast Cancer Research and Treatment|March 5, 2018
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristicsMegan S Rice, Rulla M Tamimi, Kimberly A Bertrand, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohortY Li, M Wong, L Zhan, et al.
Therapeutic Advances in Medical Oncology|September 26, 2022
Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsyMiguel Garcia-Pardo, Kasia Czarnecka, Jennifer H Law, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2020
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft modelsSebastiao N Martins-Filho, Jessica Weiss, Nhu-An Pham, et al.
The Oncologist|April 7, 2019
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence AnalysisGrainne M O'Kane, Jie Su, Brandon C Tse, et al.
Clinical Lung Cancer|May 17, 2025
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase InhibitorsLouis Pinard, Avinash Rao Ullur, Louis Everest, et al.
Pageof 129